Charles Nemeroff

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, USA
    Trials 15:240. 2014
  2. pmc Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    Trials 13:106. 2012
  3. pmc Personalized medicine in psychiatry: problems and promises
    Uzoezi Ozomaro
    University of Miami, Leonard M, Miller School of Medicine, Miami, FL, USA
    BMC Med 11:132. 2013
  4. pmc International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
    Leanne M Williams
    BRAINnet Foundation, 71 Stephenson Street, Suite 400, San Francisco, CA, 94105, USA
    Trials 12:4. 2011
  5. ncbi request reprint The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications
    R Brett Lloyd
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Top Med Chem 11:609-17. 2011

Collaborators

  • Boadie W Dunlop
  • Helen S Mayberg
  • Uzoezi Ozomaro
  • Michael Kutner
  • Becky Kinkead
  • Elisabeth B Binder
  • Mary E Kelley
  • R Brett Lloyd
  • Leanne M Williams
  • Sanjay J Mathew
  • Tanja Jovanovic
  • Barbara O Rothbaum
  • Dan V Iosifescu
  • Clinton D Kilts
  • Thomas C Neylan
  • Erica Duncan
  • Philip D Harvey
  • Claes Wahlestedt
  • Mark M Goodman
  • Joseph F Cubells
  • James C Ritchie
  • D Jeffrey Newport
  • Michael J Owens
  • W Edward Craighead
  • Drew Westen
  • Vivianne Aponte Rivera
  • Thaddeus W W Pace
  • Alan F Schatzberg
  • Stephen R Wisniewski
  • A John Rush
  • Evian Gordon
  • Nicholas J Cooper
  • Stephen H Koslow

Detail Information

Publications6

  1. pmc Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, USA
    Trials 15:240. 2014
    ..This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD...
  2. pmc Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
    Boadie W Dunlop
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1256 Briarcliff Road, Building A, 3rd Floor, Atlanta, GA 30306, USA
    Trials 13:106. 2012
    ..Consequently, we initiated a randomized clinical trial designed to identify factors that moderate response to three treatments for MDD among patients never treated previously for the condition...
  3. pmc Personalized medicine in psychiatry: problems and promises
    Uzoezi Ozomaro
    University of Miami, Leonard M, Miller School of Medicine, Miami, FL, USA
    BMC Med 11:132. 2013
    ..In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging...
  4. pmc International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
    Leanne M Williams
    BRAINnet Foundation, 71 Stephenson Street, Suite 400, San Francisco, CA, 94105, USA
    Trials 12:4. 2011
    ..The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine; and develop a model that incorporates multiple predictors and moderators...
  5. ncbi request reprint The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications
    R Brett Lloyd
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Top Med Chem 11:609-17. 2011
    ..Perhaps the best studied central nervous system (CNS) component of this system is corticotropin-releasing factor (CRF), and considerable research has focused on its role in the HPA axis, as well in extrahypothalamic brain regions...